Crystal Monroy

FDA investigator

Appears on 15 documents from 2014 to 2026, most often at sites in California. Most often cites production record review (21 CFR 211.192).

15
Documents on file
7.3
Observations per 483
2014
First seen
2026
Most recent

What they cite most

From 110 observations

Activity by year

2014: 1, 2021: 1, 2022: 5, 2023: 1, 2024: 3, 2025: 3, 2026: 1

Where

California 7 · Canada 2 · Arizona 1 · China 1 · India 1 · Japan 1

Is Crystal Monroy coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

15 documents, newest first
FirmOpen
483 K.C. Pharmaceuticals, Inc.Feb 13, 2026 · Pomona, California
483 Sparsha Pharma Usa IncSep 4, 2025 · Oceanside, California
483 NIPPON RIKA CO., LTD.Jul 4, 2025 · ASHIKAGA, Japan
483 OASIS Medical, Inc.Jan 27, 2025 · Glendora, California
483 ABRYL LABORATORIES PRIVATE LIMITEDAug 20, 2024 · SAS NAGAR, India
483 Brands International CorporationJun 21, 2024 · Newmarket, Canada
483 Amphastar Pharmaceuticals, Inc.Mar 1, 2024 · Rancho Cucamonga, California

About this profile

What does Crystal Monroy inspect?

Crystal Monroy appears on 15 documents on file covering 14 sites, most often in California.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.160 and 21 CFR 211.166.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Crystal Monroy is dated Feb 13, 2026.

FDA Investigator Crystal Monroy: 483s & Inspections · FDA Intel